# Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

> **NCT02633137** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 49 (actual)

## Conditions studied

- Mantle Cell Lymphoma
- Untreated

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** R-CHOP
- **DRUG:** high-dose cytarabine (HIDAC)

## Key facts

- **NCT ID:** NCT02633137
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-14
- **Primary completion:** 2023-11-07
- **Final completion:** 2023-11-07
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633137, "Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02633137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*